Background: Asthma is a chronic airway disease, affecting over 300 million people worldwide. 5-10% of patients suffer from severe asthma and account for 50% of the asthma related costs. Availability of data about the natural course of severe asthma is insufficient. 

Objectives: To characterize a cohort of severe asthma patients in the SSAR and evaluate predictors of asthma control.Method: Descriptive characterisation of patients (n=278), enrolled in the SSAR. Further, a comparison of patients with controlled and uncontrolled asthma was performed using multivariable regression. 

Results: The mean age was 55.8 years (13-87y) (48% female). The mean BMI was 27.4 kg/m2 (±6). 10.8% of the patients were current smokers. Most common comorbidities: Allergies (54.3%), chronic rhinosinusitis (46.4%), and nasal polyps (34.1%). ACT asthma control: well-controlled 54.7%, partly controlled: 16.2%, uncontrolled: 25.9%. Medication: ICS/LABA as most common inhalation therapy (78.8%). Monoclonal antibodies: 81.7%, and oral corticosteroids: 19.1%. Predictors of Asthma control: treatment with monoclonal antibodies was positively associated with asthma control (OR: 2.62; 95 % CI: 1.19-5.89) whereas number of exacerbations (OR: 0.63; 95 % CI: 0.5-0.78) and COPD (OR: 0.33; 95 % CI: 0.11-0.95) were negatively associated with the asthma control status. 

Conclusion: Participants in the SSAR had frequent prescription of biologics that are essential for improving symptom control in severe asthma. Further analysis will be required to complete the picture of severe asthma and provide improved management approaches.